C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 6, 2011, Pages 2450-2455

  Wang, Yue Ying ^a   Zhao, Li Juan ^a,b   Wu, Chuan Feng ^a,b   Liu, Ping ^a   Shi, Lin ^a   Liang, Yang ^a   Xiong, Shu Min ^a   Mi, Jian Qing ^a   Chen, Zhu ^a   Ren, Ruibao ^c   Chen, Sai Juan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c BRANDEIS UNIVERSITY   (United States)

Author keywords

Combinatorial therapy; Interleukin 3; Mouse model; Stem cell factor; Targeted therapy

Indexed keywords

CYTARABINE; DASATINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; FUSION GENE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA CELL; LEUKEMOGENESIS; LIFESPAN; LYMPHATIC LEUKEMIA; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE C KIT; OVERALL SURVIVAL; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTARABINE; HUMANS; LEUKEMIA, LYMPHOID; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, TRANSGENIC; MUTATION; NIH 3T3 CELLS; ONCOGENE PROTEINS, FUSION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-KIT; TRANSLOCATION, GENETIC;

ANIMALIA; MURINAE; MUS;

EID: 79952286086     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1019625108     Document Type: Article

References (35)

1. Rowley JD (2000) Molecular genetics in acute leukemia. Leukemia 14:513-517.
2. Peterson LF, Zhang DE (2004) The 8;21 translocation in leukemogenesis. Oncogene 23:4255-4262. (Pubitemid 38758592)
3. Yergeau DA, et al. (1997) Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15:303-306. (Pubitemid 27098728)
4. Higuchi M, et al. (2002) Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1:63-74. (Pubitemid 41039177)
5. Rhoades KL, et al. (2000) Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 96:2108-2115.
6. Yuan Y, et al. (2001) AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98:10398-10403. (Pubitemid 32803031)
7. de Guzman CG, et al. (2002) Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 22:5506-5517.
8. Schessl C, et al. (2005) The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 115:2159-2168. (Pubitemid 41134157)
9. Grisolano JL, O'Neal J, Cain J, Tomasson MH (2003) An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 100:9506-9511. (Pubitemid 37033958)
10. Yan M, et al. (2006) A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 12:945-949. (Pubitemid 44175147)
11. Look AT (1997) Oncogenic transcription factors in the human acute leukemias. Science 278:1059-1064.
12. Gilliland DG, Tallman MS (2002) Focus on acute leukemias. Cancer Cell 1:417-420. (Pubitemid 41039122)
13. Gilliland DG, Jordan CT, Felix CA (2004) The molecular basis of leukemia. Hematology (Am Soc Hematol Educ Program) 2004:80-97.
14. Renneville A, et al. (2008) Cooperating gene mutations in acute myeloid leukemia: A review of the literature. Leukemia 22:915-931. (Pubitemid 351709343)
15. Beghini A, et al. (2004) KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 89:920-925. (Pubitemid 39049899)
16. Goemans BF, et al. (2005) Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19:1536-1542. (Pubitemid 43090396)
17. Wang YY, et al. (2005) AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 102:1104-1109.
18. Jiao B, et al. (2009) AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 23:1598-1604.
19. Zheng X, Oancea C, Henschler R, Ruthardt M (2009) Cooperation between constitutively activated c-Kit signaling and leukemogenic transcription factors in the determination of the leukemic phenotype in murine hematopoietic stemcells. Int J Oncol 34:1521-1531.
20. Lev S, Blechman J, Nishikawa S, Givol D, Yarden Y (1993) Interspecies molecular chimeras of kit help define the binding site of the stem cell factor. Mol Cell Biol 13:2224-2234. (Pubitemid 23097701)
21. Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH (2007) Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol 27:267-282. (Pubitemid 46013250)
22. Longley BJ, et al. (1996) Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 12:312-314. (Pubitemid 26080092)
23. Hirota S, et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580. (Pubitemid 28067289)
24. Kontogianni-Katsarou K, et al. (2008) KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential. World J Gastroenterol 14:1891-1897. (Pubitemid 351523820)
25. Ma Y, et al. (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741-1744. (Pubitemid 34533049)
26. Foster R, Griffith R, Ferrao P, Ashman L (2004) Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 23:139-152. (Pubitemid 39195283)
27. Mol CD, et al. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279:31655-31663. (Pubitemid 39037836)
28. Schindler T, et al. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942.
29. Shah NP, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401. (Pubitemid 38938156)
30. Schittenhelm MM, et al. (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66:473-481. (Pubitemid 43166056)
31. Boissel N, et al.; Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups (2006) Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20:965-970.
32. Cairoli R, et al. (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107:3463-3468.
33. Gross AW, Zhang X, Ren R (1999) Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol 19:6918-6928. (Pubitemid 29441874)
34. Zhang X, Ren R (1998) Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92:3829-3840. (Pubitemid 28525209)
35. Parikh C, Subrahmanyam R, Ren R (2006) Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 108:2349-2357. (Pubitemid 44497519)